Skip to Main Content

Author Details

Andrew E Aplin
Thomas Jefferson University
1996
162
49
Prashant Mali (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37847239SOX10 Loss Sensitizes Melanoma Cells to Cytokine-Mediated Inflammatory Cell Death.Mol Cancer Res2024
36223548IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression.Mol Cancer Ther2023
37636077Gene signature reveals decreased SOX10-dependent transcripts in malignant cells from immune checkpoint inhibitor-resistant cutaneous melanomas.iScience2023
37543514Targeting TEAD-ious resistance.Trends Cancer2023
37605008MacroH2A restricts inflammatory gene expression in melanoma cancer-associated fibroblasts by coordinating chromatin looping.Nat Cell Biol2023
37343247Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant Melanoma.Mol Cancer Ther2023
37444561Co-Targeting FASN and mTOR Suppresses Uveal Melanoma Growth.Cancers (Basel)2023
37331825Site matters in metastatic melanoma.Trends Cancer2023
36795483Lysosomal lipid peroxidation regulates tumor immunity.J Clin Invest2023
36598655Engaging community members in cancer research: an assessment of an NCI-designated cancer center.Cancer Causes Control2023
35296667Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma.Nat Commun2022
35652219Packing a Punch against PD-L1.Cancer Discov2022
35426938Multi-omics Profiling Shows BAP1 Loss Is Associated with Upregulated Cell Adhesion Molecules in Uveal Melanoma.Mol Cancer Res2022
35657206A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in NRAS Mutant Melanoma.Cancer Res2022
35513054The future of targeted kinase inhibitors in melanoma.Pharmacol Ther2022
36044013Raptinal Induces Gasdermin E-Dependent Pyroptosis in Naïve and Therapy-Resistant Melanoma.Mol Cancer Res2022
36230787Lysine Methyltransferase NSD1 and Cancers: Any Role in Melanoma?Cancers (Basel)2022
35046531Pyruvate dehydrogenase inactivation causes glycolytic phenotype in BAP1 mutant uveal melanoma.Oncogene2022
35147163RAS-mediated tumor stress adaptation and the targeting opportunities it presents.Dis Model Mech2022
35086548Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathway.J Exp Clin Cancer Res2022
33000894Role of serine 365 in BRAF V600E sensitivity to RAF inhibition.Pigment Cell Melanoma Res2021
33545064Melanoma models for the next generation of therapies.Cancer Cell2021
33568347Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for <i>GNAQ</i>-Driven Uveal Melanoma.Clin Cancer Res2021
33510355Correction to: BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors.Oncogene2021
33806615Dual Targeting of CDK4/6 and cMET in Metastatic Uveal Melanoma.Cancers (Basel)2021
35121999PROactively TACkling CDK4/6 therapy resistance.Nat Cancer2021
34879275SOX10 requirement for melanoma tumor growth is due, in part, to immune-mediated effects.Cell Rep2021
34479970From the Community to the Bench and Back Again: The Value of Patient and Community Engagement in Cancer Research.Cancer Discov2021
34389658Correction: Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for <i>GNAQ</i>-Driven Uveal Melanoma.Clin Cancer Res2021
34127435Metabolic Alterations and Therapeutic Opportunities in Rare Forms of Melanoma.Trends Cancer2021
33060121The Latest on Uveal Melanoma Research and Clinical Trials: Updates from the Cure Ocular Melanoma (CURE OM) Science Meeting (2019).Clin Cancer Res2021
33452215Combined SHPments: An Effective Therapeutic Strategy for MPNST.Cancer Res2021
33451983Fueling the Fire: Inflammatory Forms of Cell Death and Implications for Cancer Immunotherapy.Cancer Discov2021
33446574Roles of the BAP1 Tumor Suppressor in Cell Metabolism.Cancer Res2021
33208912BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors.Oncogene2021
32430489Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma.Mol Cancer Ther2020
31932756Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma.Br J Cancer2020
31696640PLX3397 inhibits the accumulation of intra-tumoral macrophages and improves bromodomain and extra-terminal inhibitor efficacy in melanoma.Pigment Cell Melanoma Res2020
31796433Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis.Cancer Discov2020
31940493FOXD3 Regulates VISTA Expression in Melanoma.Cell Rep2020
33037411S6K1 blockade overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.Oncogene2020
32661093Activation of CD8<sup>+</sup> T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors.Cancer Immunol Res2020
32389536Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase Inhibition.J Invest Dermatol2020
30610113Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma.EMBO Mol Med2019
31270153<i>In Vivo</i> ERK1/2 Reporter Predictively Models Response and Resistance to Combined BRAF and MEK Inhibitors in Melanoma.Mol Cancer Ther2019
31239444m<sup>6</sup>A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade.Nat Commun2019
31375579Murine Cytomegalovirus Infection of Melanoma Lesions Delays Tumor Growth by Recruiting and Repolarizing Monocytic Phagocytes in the Tumor.J Virol2019
31251472C57BL/6 congenic mouse NRAS<sup>Q61K</sup> melanoma cell lines are highly sensitive to the combination of Mek and Akt inhibitors in vitro and in vivo.Pigment Cell Melanoma Res2019
31063649The next-generation BET inhibitor, PLX51107, delays melanoma growth in a CD8-mediated manner.Pigment Cell Melanoma Res2019
30703359BET Inhibition Modifies Melanoma Infiltrating T Cells and Enhances Response to PD-L1 Blockade.J Invest Dermatol2019
  • 1 - 50 of 162

Recommended Authors

Andrew McNeal
University of California San Francisco
Career Start Year 2014
Number of shared co-authors 1
Shruthy Suresh
Memorial Sloan Kettering Cancer Center
Career Start Year 2013
Number of shared co-authors 2
Brian J Capaldo
Center for Cancer Research, National Cancer Institute
Career Start Year 2012
Number of shared co-authors 0
Luping Lin
Incyte Research Institute, Incyte Corporation
Career Start Year 2010
Number of shared co-authors 0
Giuseppina Claps
Institut National de la Sante et de la Recherche Medicale (INSERM) U
Career Start Year 2010
Number of shared co-authors 7
Aleksandra M Michalowski
Center for Cancer Research, National Cancer Institute
Career Start Year 2010
Number of shared co-authors 4
Guo Chen
China Pharmaceutical University
Career Start Year 2009
Number of shared co-authors 10
Eva P??rez-Guijarro
National Cancer Institute, National Institutes of Health (NIH)
Career Start Year 2009
Number of shared co-authors 11
Nina Fenouille
Universite Paris Cite, INSERM, CNRS
Career Start Year 2008
Number of shared co-authors 0
Michael P O'Connell
National Institute of Allergy and Infectious Diseases, National Institutes of Health
Career Start Year 2007
Number of shared co-authors 7
Shweta Joshi
Moores Cancer Center, University of California
Career Start Year 2007
Number of shared co-authors 0
M Raza Zaidi
Northwell Health Cancer Institute
Career Start Year 2006
Number of shared co-authors 11
Joshua C Anderson
University of Alabama at Birmingham
Career Start Year 2005
Number of shared co-authors 0
Kris C Wood
Duke University
Career Start Year 2005
Number of shared co-authors 3
Christine A Pratilas
Johns Hopkins University School of Medicine
Career Start Year 2004
Number of shared co-authors 2
Harriet M Kluger
Yale School of Medicine
Career Start Year 2003
Number of shared co-authors 9
Hussein A Tawbi
MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 21
Yongmei Feng
Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2002
Number of shared co-authors 12
Daniel Zingg
Netherlands Cancer Institute
Career Start Year 2001
Number of shared co-authors 4
Todd D Prickett
National Cancer Institute
Career Start Year 2000
Number of shared co-authors 5
Christopher D Willey
University of Alabama at Birmingham
Career Start Year 2000
Number of shared co-authors 0
Bartosz Chmielowski
Jonsson Comprehensive Cancer Center, University of California Los Angeles
Career Start Year 1999
Number of shared co-authors 4
Cindy Sander
UPMC Hillman Cancer Center
Career Start Year 1997
Number of shared co-authors 6
Theresa M LaVallee
Parker Institute for Cancer Immunotherapy
Career Start Year 1996
Number of shared co-authors 2
Richard W Joseph
Mayo Clinic Hospital
Career Start Year 1994
Number of shared co-authors 5
Krister Wennerberg
University of Copenhagen
Career Start Year 1994
Number of shared co-authors 0
Livio Trusolino
Candiolo Cancer Institute - FPO IRCCS
Career Start Year 1993
Number of shared co-authors 2
Levi A Garraway
Broad Institute of Harvard and MIT
Career Start Year 1991
Number of shared co-authors 12
Francisca Vazquez
Broad Institute of MIT and Harvard
Career Start Year 1979
Number of shared co-authors 2
Menashe Bar-Eli
The University of Texas MD Anderson Cancer Center
Career Start Year 1975
Number of shared co-authors 9

Collaborators

Michael A Davies
The University of Texas MD Anderson Cancer Center
Co-authored papers 19
Takami Sato
Sidney Kimmel Cancer Center, Thomas Jefferson University
Co-authored papers 16
Manoela Tiago
Thomas Jefferson University
Co-authored papers 13
Marcus Bosenberg
Yale School of Medicine
Co-authored papers 8
Meenhard Herlyn
Ellen and Ronald Caplan Cancer Center, The Wistar Institute
Co-authored papers 8
Heinz Arnheiter
National Institute of Neurological Disorders and Stroke, National Institute of Health
Co-authored papers 7
Reinhard Dummer
University Hospital Zurich
Co-authored papers 6
Glenn Merlino
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 5
Mitchell P Levesque
University Hospital Zurich
Co-authored papers 5
Phil F Cheng
University Hospital of Zurich
Co-authored papers 5
Ashani T Weeraratna
Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine
Co-authored papers 4
David W Speicher
Co-authored papers 4
Katherine L Nathanson
Perelman School of Medicine, University of Pennsylvania, USA Abramson Cancer Center
Co-authored papers 3
Jeffrey E Gershenwald
The University of Texas MD Anderson Cancer Center
Co-authored papers 3
Chi-Ping Day
Center for Cancer Research, National Cancer Institute
Co-authored papers 3
Georgina V Long
Co-authored papers 3
Rong Hu
Co-authored papers 3
Lawrence N Kwong
The University of Texas MD Anderson Cancer Center
Co-authored papers 3
Jennifer A Wargo
Co-authored papers 3
Gaurav Kumar
Gladstone Institutes
Co-authored papers 2
Ze'ev Ronai
Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
Co-authored papers 2
Jonathan A Pachter
Laufer Center for Physical and Quantitative Biology, Stony Brook University
Co-authored papers 2
Kyle Ford
University of California San Diego
Co-authored papers 2
Prashant Mali (CM4AI)
University of California San Diego
Co-authored papers 2
Jorge Silvio Gutkind
Moores Cancer Center, University of California San Diego
Co-authored papers 2
Justine S Paradis
Moores Cancer Center, University of California San Diego
Co-authored papers 2
Nadia Arang
Moores Cancer Center, University of California San Diego
Co-authored papers 2
Michael R Emmert-Buck
The Francis Crick Institute
Co-authored papers 2
Xingyu Wu
Moores Cancer Center, University of California San Diego
Co-authored papers 2
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 2
Release 1.2